Prelude Therapeutics Inc (PRLD) saw an uptrend of 21.43% in the recent trading with $2.21 being its most recent. The current price level -47.63% lower than the highest price of $4.22 marked by the stock while trading over the past 52-weeks, whereas it is 262.24% higher than the lowest price of $0.61 the company dropped to over past 52-weeks. The latest news story on PRLD appeared in (GlobeNewswire) under the title “Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Prelude Therapeutics Inc Earnings – What Happened With PRLD
Coming around sales and income figures on PRLD Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Prelude Therapeutics Inc (PRLD) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 20.81% for net revenue.
PRLD – Prelude Therapeutics Inc Stock Earnings Estimates
The perspective of Prelude Therapeutics Inc (NASDAQ:PRLD)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.47 for stock’s EPS in the current quarter. Prelude Therapeutics Inc (PRLD) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 20.81% for net revenue. Company’s EPS for the last quarter was -0.37.
Prelude Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 43.75 million. PRLD does have institutional investors; and they hold 28.76% of the stock.
As on 2024-06-30, ORBIMED ADVISORS LLC was the top most holder in Prelude Therapeutics Inc (NASDAQ:PRLD) with an ownership of 10.91 million shares of the company or 14.4043 of the stake worth $41.56 million. The filing also reveals BAKER BROS. ADVISORS LP as the second largest holder in the company with a control over 13.3673 of the outstanding shares. Its stake is worth $38.57 million for having 10.12 million shares in hand.
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) also came holding a key position in the company during the recent quarter and it now holds 5.4571 of the outstanding shares. With this there are now 61.0 institutions which have possession in PRLD’s shares.
Key Metrics for PRLD
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Prelude Therapeutics Inc has a debt to equity ratio of 0.30.
